Pharmacogenetic Prediction in Colorectal Cancer Treatment
Author Information
Author(s): Paré L, Marcuello E, Altés A, Río E del, Sedano L, Salazar J, Cortés A, Barnadas A, Baiget M
Primary Institution: Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hypothesis
Can genetic polymorphisms predict clinical outcomes in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy?
Conclusion
The study found that certain genetic polymorphisms can predict the response and survival outcomes in colorectal cancer patients treated with oxaliplatin-based chemotherapy.
Supporting Evidence
- Patients with the ERCC1-118 TT or CT genotype had a 3.7 times greater probability of response compared to those with the CC genotype.
- Median progression-free survival was 10 months for TT and CT cases compared to 6 months for CC patients.
- Median overall survival was 30 months for TT and CT cases compared to 11 months for CC cases.
Takeaway
Doctors can use specific genes to help decide how well a cancer treatment might work for patients with colorectal cancer.
Methodology
The study involved 126 colorectal cancer patients treated with oxaliplatin and 5-fluorouracil, analyzing genetic polymorphisms to predict clinical outcomes.
Potential Biases
Potential biases may arise from the selection of patients and the assessment of clinical outcomes.
Limitations
The study may not account for all genetic factors influencing treatment response and was limited to a specific patient population.
Participant Demographics
The study included 126 patients, with a median age of 66 years, consisting of 64% men and 36% women.
Statistical Information
P-Value
P=0.008 for ERCC1-118 significance
Confidence Interval
95% CI: 1.4–9 for response probability
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website